CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

• Conditions: Multiple Myeloma

• Registration Number: NCT00044018
• Lead Sponsor: Celgene

Brief Summary

The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-04-01
• Study First Submitted: 2002-08-16
• Study First Submitted QC: 2002-08-19
• Study First Posted: 2002-08-20
• Primary Completion: 2004-12-01
• Study Completion: 2007-02-15
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-07
• Last Update Posted: 2019-11-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 102

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Confirmed M-Protein Response During Single Agent CDC-501 Therapy	Response assessed every 4 weeks; up to 62 months	M-Protein response evaluated every 4 weeks through urine and serum electrophoresis.

Trial Locations

Locations (4)

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

St Vincent's Cancer Center; 🇺🇸 New York, New York, United States

H Lee Moffit Cancer Center; 🇺🇸 Tampa, Florida, United States